{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:00:21Z","timestamp":1788822021916,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T00:00:00Z","timestamp":1369699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (<jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content>). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma (<jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content>) is not well described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To determine the efficacy of oral anti\u2010viral agents in reducing <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> risk in relationship with other known factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Published studies of at least 20 <jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content> patients treated with an oral anti\u2010viral agent and followed for &gt;2\u00a0years were analysed for incidence of <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> per 100 person years follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pooled homogeneous data from six studies showed lamivudine (<jats:styled-content style=\"fixed-case\">LAM<\/jats:styled-content>) treatment (<jats:italic>n<\/jats:italic>\u00a0=\u00a03306) to reduce <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> risk by 51% compared with no treatment (<jats:italic>n<\/jats:italic>\u00a0=\u00a03585) (3.3 vs. 9.7 per 100 person years, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). Pooled data from 49 studies (23 with <jats:styled-content style=\"fixed-case\">LAM<\/jats:styled-content>; 16 with adefovir; and 10 with entecavir, tenofovir or telbivudine) of 10\u00a0025 treated patients showed <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> incidence of 1.3 per 100 person years, independent of the agent used. Patient age &gt;50\u00a0years and hepatitis B virus\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> detectability at <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> diagnosis increased risk of <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> by twofold with a 10\u2010fold higher risk among patients with cirrhosis compared with chronic hepatitis. Meta\u2010regression showed patient age, study location (Eastern vs. Western) and type of study (randomised or not) contributed to heterogeneity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Lamivudine treatment significantly reduces the incidence of <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> compared with no treatment. However, <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> still develops at a rate of 1.3 per 100 patient years in <jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content> patients receiving an oral anti\u2010viral agent. This finding highlights the need for continued <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> surveillance, particularly in <jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content> patients with inadequate viral suppression, older age and cirrhosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.12344","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T05:18:06Z","timestamp":1369804686000},"page":"98-106","source":"Crossref","is-referenced-by-count":143,"title":["Meta\u2010analysis: the impact of oral anti\u2010viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B"],"prefix":"10.1111","volume":"38","author":[{"given":"A. K.","family":"Singal","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology University of Alabama Birmingham AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Salameh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine UTMB Galveston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.\u2010F.","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Geriatrics and Biostatistics UTMB Galveston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Fontana","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology University of Michigan Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.12.061"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25937"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013215"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033364"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04990.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.035"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00785.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01301.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.011"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.221846"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25869"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115507"},{"key":"e_1_2_7_16_1","article-title":"Long\u2010term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","author":"Hosaka T","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.003"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.11.011"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9080-3"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01297149"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.08.019"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210114"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260536"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00272.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.07057.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12344","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T14:55:26Z","timestamp":1696344926000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,28]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1111\/apt.12344"],"URL":"https:\/\/doi.org\/10.1111\/apt.12344","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,28]]}}}